The effect of risperidone on nursing burden associated with caring for patients with dementia.
OBJECTIVE
To compare risperidone treatment with placebo for the burden to nursing staff of older nursing-home residents with dementia.


METHODS
Randomized, double-blind, placebo-controlled trial.


METHODS
Long-term care institutions in Australia and New Zealand.


METHODS
Two hundred seventy-nine residents had evaluable data for comparison of oral risperidone with placebo treatment at 4 weeks, 8 weeks, and endpoint across the 12-week trial.


METHODS
The Modified Nursing Care Assessment Scale (M-NCAS) is a 28-item instrument that measures behavior occurrence in patients (patient outcome) and difficulty of those behaviors for nursing staff as rated by nurse carers (nurse outcome). Treatment groups were compared via analysis of covariance (ANCOVA). To aid score interpretation, M-NCAS effect sizes were examined by response category, with response defined as subjects with mean Cohen-Mansfield Agitation Inventory total aggression subscale score change of 4 points or greater, a clinical outcome for patients.


RESULTS
Between-group ANCOVAs showed statistically significant reductions in nurse-rated M-NCAS scores from baseline to endpoint for the patients randomized to risperidone relative to placebo (P<.05). Effects were evident at 4 weeks and maintained over time. Effect sizes were moderate to large for responders and near zero for nonresponders.


CONCLUSIONS
Risperidone treatment was associated with an early and sustained reduction in nursing staff burden as measured using the M-NCAS compared with placebo treatment for older nursing home residents with dementia.
Frank
Lori
L
MEDTAP International, Bethesda, Maryland 20814, USA. frank@medtap.com
Kleinman
Leah
L
Ciesla
Gabrielle
G
Rupnow
Marcia F T
MF
Brodaty
Henry
H
D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001291:Attitude of Health Personnel; D001315:Australia; D017281:Cost of Illness; D003704:Dementia / Q000150:complications / Q000188:drug therapy* / Q000451:nursing*; D004311:Double-Blind Method; D005260:Female; D015577:Geriatric Assessment; D006801:Humans; D008134:Long-Term Care / Q000458:organization & administration; D008137:Longitudinal Studies; D008297:Male; D009520:New Zealand; D009735:Nursing Homes / Q000458:organization & administration; D009740:Nursing Staff / Q000523:psychology; D011595:Psychomotor Agitation / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control; D018967:Risperidone / Q000627:therapeutic use*; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires; D013997:Time Factors; D016896:Treatment Outcome; D016526:Workload / Q000706:statistics & numerical data
D014150:Antipsychotic Agents; D018967:Risperidone